share_log

Alliance Global Partners Initiates Coverage On Akari Therapeutics With Buy Rating, Announces Price Target of $4

Alliance Global Partners Initiates Coverage On Akari Therapeutics With Buy Rating, Announces Price Target of $4

聯盟全球合作伙伴以買入評級啓動對Akari Therapeutics的報道,宣佈目標股價爲4美元
Benzinga Real-time News ·  2022/11/01 08:58

Alliance Global Partners analyst James Molloy initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $4.

Alliance Global Partners分析師詹姆斯·莫洛伊對阿卡里治療公司(納斯達克代碼:AKTX)的報道給予買入評級,並宣佈目標價為4美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論